PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
Peey‐Sei Kok(The University of Sydney), Anna DeFazio(The University of Sydney), Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Rachel O’Connell(Royal Marsden NHS Foundation Trust), Yoland Antill(Peninsula Health), Cristina Mapagu(The University of Sydney), Tony Bonaventura(St Vincent’s Private Hospital Sydney), Peter Grant(The University of Melbourne), James Scurry, Katrin Marie Sjoquist(Australian Research Council), Jeffrey C. Goh(The University of Queensland)
Cited by 26
Related Papers
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Driver mutations in <i>TP53</i> are ubiquitous in high grade serous carcinoma of the ovary
|The Journal of Pathology|2010|836
Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary
|New England Journal of Medicine|2009|775